Ipca Laboratories Ltd Q1 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/pv14d9xb601cvsuzmo09ivly.pdf

Key Takeaways


Domestic & Branded Formulation Momentum

A. K. Jain: "practically the KSM manufacturers are losing money now at that level. So, it is not that these things will continue for very long, maybe matter of 6 months, the KSM prices will again start rising."

API Headwinds & KSM Price Collapse


Margin Walk & Cost Drivers


Unichem Acquisition & Integration

A. K. Jain: "practically on ground actions will start only after completely we are in the management here."

US FDA & Regulatory Pathway

A. K. Jain: "There are no repeat observations and also there are no kind of data integrity kind of issues. So, hopefully we should get cleared and I think it is only a matter of time..."

Dewas Site & Continuous Process Plant


Guidance & Commitments

CommitmentSpecificsTimeline
Domestic formulation growth~12% to 14% growthFY24
Branded export formulation growth~12% to 14% growth (lower due to currency depreciation)FY24
Generic formulation export growth~7% to 8% growthFY24
Institutional antimalarial decline~15% declineFY24
API business decline~10% to 12% declineFY24
Overall revenue growthSingle digit to ~6%-8%FY24
Material cost to sales ratio~31.5% to 32% (improvement of ~3.5%-4%)FY24
EBITDA margin~19% to 19.5% (excluding other income)FY24
API business normalized growth~10% to 12% growthFY25 (next year)
KSM price recoveryPrices to start rising again as manufacturers are losing money~6 months
WHO sterile Artesunate approvalApproval expected, injectable shipments to resume thereafter~1 month
Unichem management controlOpen offer closes, payments made, control obtainedSeptember-end
Unichem major consolidationFinancial and operational consolidation beginsQ3 FY24 onwards
Dewas site inspectionsEuropean and other authority inspections beginH2 FY24
Continuous process plant startFurosemide production begins via continuous processOctober-November
One cardiovascular division breakevenDivision reaches breakevenNext financial year

Key Metrics

MetricQ1 FY24
Domestic formulation growth~14% YoY
Domestic formulation growth vs industry~13% for Ipca vs ~11% for industry as per IQVIA
Export branded formulation revenue~₹114 cr, up ~23% YoY from ₹93 cr
Generic formulation revenue (excl. institutional)~₹235 cr, up 11% YoY from ₹212 cr
Institutional antimalarial revenue₹48 cr, down from ₹97 cr YoY
API revenue₹295 cr, down ~23% YoY from ₹384 cr
Antimalarial API revenue₹19 cr, down from ₹63 cr YoY, a decline of ~₹44 cr
Standalone profit after tax₹166.58 cr
Consolidated profit after tax₹162.82 cr, drag from subsidiaries of ~₹3.76 cr
EBITDA margin (standalone, excl. other income)16.26% in FY23, guidance of ~19% to 19.5% for FY24
Material cost to sales ratioExpected to improve from ~35.5% in FY23 to ~31.5%–32% in FY24
Overall revenue growth guidance for FY24~6% to 8%
Field force size~6,180 people
Monthly field force productivity~₹4.22 lakhs, up from ₹4.08 lakhs YoY
Europe (incl. UK) formulation revenue~₹119 cr, up ~63% YoY from ₹73 cr
CAPEX guidance for FY24~₹300 cr